BioCentury
ARTICLE | Targets & Mechanisms

Triplet brings a new strategy to Huntington’s disease

Unveils preclinical POC data for its first DNA damage repair target

April 27, 2021 11:30 PM UTC

Preclinical data suggest that with a new target and route of administration, Triplet’s antisense oligonucleotide for Huntington’s disease may be effective where others have fallen ...



Access this Article

BCIQ Company Profiles

Triplet Therapeutics Inc.